<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287103</url>
  </required_header>
  <id_info>
    <org_study_id>0160-14-WOMC</org_study_id>
    <nct_id>NCT02287103</nct_id>
  </id_info>
  <brief_title>Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Lunch and Dinner in T2D</brief_title>
  <acronym>SkippB-T2D</acronym>
  <official_title>Effect of Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Subsequent Isocaloric Lunch and Dinner in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel Aviv University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Skipping breakfast and/or overeating at evening, has been associated in type 2
      diabetic (T2D) individuals, with higher BMI, visceral adiposity, hyperlipidemia, increased
      overall postprandial glycemia (PPHG) and higher HbA1c. The absence of breakfast is also
      associated with increased plasma free fatty acids (FFA) along the morning until lunch. High
      plasma FFA in turn are triggering factor of insulin resistance, by inhibiting insulin
      mediated glucose uptake in obese and T2D subjects The investigators therefore hypothesize
      that compared to eating breakfast the prolonged overnight fasting caused by the breakfast
      omission will result in increased postprandial glycemic response after subsequent isocaloric
      lunch and dinner in T2D individuals.

      Objectives: With this aim will study T2D patients in randomized crossover design to consume
      in two separate days, either 3 standard isocaloric meals: Yes Breakfast condition (YesB) or
      omit breakfast: no breakfast condition (NoB) and consume only lunch and dinner with the same
      caloric content.

      Methods and Study Design: The YesB intervention will consist on three identical meals coating
      700 Kcal each: breakfast at 8:00, lunch at 13:00 and dinner at 19:00. The NoB intervention
      the breakfast will be omitted and the subject continue fasting until lunch. Then the
      participants will consume identical 700 kcal Lunch at 13:00 and 700 Kcal dinners at 19:00.
      The investigators will assess plasma glucose, insulin, C-peptide, GLP-1 and FFA with blood
      samples collected every 30 min up to 180 min after breakfast, lunch and dinner and at the
      same time point the blood samples will be collected after 8:00 when the breakfast will be
      omitted.

      Expected results: The investigators expect that compared to NoB condition, in the YesB
      condition the postprandial response after lunch and dinner will be reduced for glucose and
      for FFA, while plasma insulin, C-peptide and GLP-1 postprandial response after lunch and
      dinner will be enhanced
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background or Rationale Studies analyzing the postprandial glycemic response have shown that
      glucose tolerance display a clear diurnal variation with a progressive decline in
      carbohydrate tolerance toward the evening hours with more prolonged and higher postprandial
      glycemic response in the evening than in the morning.

      Meal timing patterns, on the other hand, exerts strong entraining influence on clock gene
      regulation of hormones and enzymes i.e. insulin, GLP-1, involved in glucose metabolism and
      postprandial glycemia disrupting the diurnal variation of postprandial glycemia (PPG). It
      suggests the extent of post-prandial rise in plasma glucose depends not only upon the
      quantity and nature of food ingested, and on the clock gene regulated circadian hormonal
      rhythms, it also depends upon the metabolic state immediately prior to eating. Indeed, meal
      schedule non-aligned with the clock gene circadian rhythms, such as skipping breakfast and/or
      overeating at evening, has been associated, in T2D individuals, with higher BMI, visceral
      adiposity, hyperlipidemia, higher HbA1c and increased PPG despite same caloric intake. The
      absence of breakfast has been associated in obese and T2D subjects with increased plasma
      levels of free fatty acids (FFA) along the morning until the lunch, Chronic and acute
      increase of FFA plasma levels, has been reported as triggering factor of insulin resistance,
      by inhibition of insulin mediated stimulated glucose uptake and/or phosphorylation which
      develops 3-4 hours after raising of plasma FFA and by inhibition of glycogen synthase, the
      rate limiting enzyme of glycogen synthesis, which develops 4-6 hours after the rise of FFA.
      However the effect of eating vs skipping breakfast on postprandial glucose response after
      identical lunch and dinner has not been explored. It is therefore important to explore the
      influence of eating versus skipping breakfast on postprandial glucose, after lunch and dinner
      in T2D individuals. Concomitantly the investigators will assess after lunch and dinner plasma
      insulin, GLP-1 and FFA response after lunch and dinner in T2D individuals.

      Expected results: The investigators expect that compared skipping breakfast condition, the
      eating breakfast condition will reduce postprandial plasma glucose and FFA response after
      lunch and dinner, while plasma insulin, C-peptide and GLP-1 after lunch and dinner will be
      enhanced Relevance of the study: If our hypothesis is confirmed it may be may be of practical
      benefit to people with Type 2 diabetes, a condition in which the reduction of PPHG at lunch
      and at dinner may result in improved HbA1c and might be also preventive of the risk for CVD
      Objectives: With this aim will study T2D patients in randomized crossover design to consume
      in two separate days, either 3 standard isocaloric meals: Yes Breakfast condition (YesB) or
      omit breakfast: no breakfast condition (NoB) and consume only lunch and dinner with the same
      caloric content.

      Methods and Study Design: The YesB intervention will consist on three identical meals coating
      700 Kcal each: breakfast at 8:00, lunch at 13:00 and dinner at 19:00. The NoB intervention
      the breakfast will be omitted and the subject continue fasting until lunch. Then the
      participants will consume identical 700 kcal Lunch at 13:00 and 700 Kcal dinners at 19:00.
      The investigators will assess plasma glucose, insulin, C-peptide, GLP-1 and FFA with blood
      samples collected every 30 min up to 180 min after breakfast, lunch and dinner and at the
      same time point the blood samples will be collected after 8:00 when the breakfast will be
      omitted.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of plasma glucose</measure>
    <time_frame>5 weeks</time_frame>
    <description>Postprandial glycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of plasma Insulin</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of plasma GLP-1</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of free fatty acids (FFA)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breakfast</condition>
  <arm_group>
    <arm_group_label>Skipping Breakfast (NoB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eating Breakfast (YesB):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skipping Breakfast</intervention_name>
    <description>NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.</description>
    <arm_group_label>Skipping Breakfast (NoB)</arm_group_label>
    <other_name>omitting breakfast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eating Breakfast</intervention_name>
    <description>YesB: will eat all three meals</description>
    <arm_group_label>Eating Breakfast (YesB):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2D since &lt; 10 yrs, with HbA1c &gt; 7 % and BMI: 26-34 kg/m2.

          -  Only na√Øve or treated with oral antidiabetic drugs and with anti-hypertensive and
             lipid-lowering medication will be included.

          -  Those treated with insulin or GLP-1 analogs or having major liver, heart or kidney
             illnesses will be excluded.

        Exclusion Criteria:

          1. Type 1 DM, secondary DM, gestational DM

          2. Patients using insulin, TZDs

          3. Patients using corticosteroid, herb medication or other medications affecting glucose
             tolerance

          4. Renal dysfunction (Cr &gt; 1.5mg/dL)

          5. Hepatic dysfunction (LFT &gt; x 3UNL)

          6. Anemia (Hg &gt; 10g/dL)

          7. Ischemic heart disease, congestive heart failure

          8. Severe diabetic complication (CRF, CVA, PDR, gastroparesis)

          9. Infectious disease

         10. Malignancy

         11. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Jakubowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Unit E. Wolfson Medical center Holon, Tel Aviv Israe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Jakubowicz, MD</last_name>
    <phone>972508105552</phone>
    <email>daniela.jak@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julio Wainstein, MD</last_name>
    <phone>972506296940</phone>
    <email>vainstein@wolfson.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes Unit E. Wolfson Medical center</name>
      <address>
        <city>Holon</city>
        <state>Tel Aviv</state>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Jakubowicz, MD</last_name>
      <phone>972508105552</phone>
      <email>daniela.jak@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Julio Wainstein, MD</last_name>
      <phone>97254522296</phone>
      <email>vainstein@wolfson.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Jakubowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel Aviv University</investigator_affiliation>
    <investigator_full_name>Daniela Jakubowicz</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Skipping Breakfast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

